HRS 4508
Alternative Names: HRS-4508Latest Information Update: 19 Nov 2024
Price :
$50 *
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 30 Sep 2024 Jiangsu HengRui Medicine plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in China in September 2024 (NCT06598735)
- 19 Sep 2024 Preclinical trials in Solid tumours in China (unspecified route) before September 2024